European Journal of Heart Failure最新文献

筛选
英文 中文
Reply to the letter regarding the article 'Oral ferric maltol improves iron deficiency anaemia in patients with chronic heart failure'. 回复关于“口服麦芽糖醇铁改善慢性心力衰竭患者缺铁性贫血”一文的信函。
IF 18.2 1区 医学
European Journal of Heart Failure Pub Date : 2025-09-08 DOI: 10.1002/ejhf.70029
Tibor Kempf,Jan Fuge,Johann Bauersachs
{"title":"Reply to the letter regarding the article 'Oral ferric maltol improves iron deficiency anaemia in patients with chronic heart failure'.","authors":"Tibor Kempf,Jan Fuge,Johann Bauersachs","doi":"10.1002/ejhf.70029","DOIUrl":"https://doi.org/10.1002/ejhf.70029","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"15 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter regarding the article 'Association between antecedent myocardial infarction and heart failure with preserved versus reduced ejection fraction'. 关于“既往心肌梗死和心力衰竭与保持射血分数和降低射血分数之间的关系”这篇文章的信。
IF 18.2 1区 医学
European Journal of Heart Failure Pub Date : 2025-09-08 DOI: 10.1002/ejhf.70045
Hui-Chin Chang,Shuo-Yan Gau
{"title":"Letter regarding the article 'Association between antecedent myocardial infarction and heart failure with preserved versus reduced ejection fraction'.","authors":"Hui-Chin Chang,Shuo-Yan Gau","doi":"10.1002/ejhf.70045","DOIUrl":"https://doi.org/10.1002/ejhf.70045","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"57 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial. Sacubitril/缬沙坦与依那普利治疗慢性Chagas心肌病合并心力衰竭:PARACHUTE-HF试验的基线特征
IF 18.2 1区 医学
European Journal of Heart Failure Pub Date : 2025-09-08 DOI: 10.1002/ejhf.70026
Luis Eduardo Echeverria,Edimar Bocchi,Caroline Demacq,Pedro Gabriel Melo de Barros E Silva,Lu-May Chiang,Sarfaraz Sayyed,Lucas Petri Damiani,Lilian Mazza Barbosa,Remo Holanda de Mendonça Furtado,Carlos A Morillo,Ruben Kevorkian,Felix Ramires,Maria Cecilia Bahit,Adolfo Chavez-Mendoza,José Antonio Magaña-Serrano,Justo Carbajales,Wilson Oliveira Junior,Israel Molina,Arguinaldo F Freitas Junior,Maria da Consolaçao Moreira,Adegil Henrique Silva,Telemaco Silva Junior,Wladimir Saporito,José Francisco Kerr Saraiva,Claudio Gimpelewicz,John J V McMurray,Renato Delascio Lopes,
{"title":"Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure: Baseline characteristics of the PARACHUTE-HF trial.","authors":"Luis Eduardo Echeverria,Edimar Bocchi,Caroline Demacq,Pedro Gabriel Melo de Barros E Silva,Lu-May Chiang,Sarfaraz Sayyed,Lucas Petri Damiani,Lilian Mazza Barbosa,Remo Holanda de Mendonça Furtado,Carlos A Morillo,Ruben Kevorkian,Felix Ramires,Maria Cecilia Bahit,Adolfo Chavez-Mendoza,José Antonio Magaña-Serrano,Justo Carbajales,Wilson Oliveira Junior,Israel Molina,Arguinaldo F Freitas Junior,Maria da Consolaçao Moreira,Adegil Henrique Silva,Telemaco Silva Junior,Wladimir Saporito,José Francisco Kerr Saraiva,Claudio Gimpelewicz,John J V McMurray,Renato Delascio Lopes, ","doi":"10.1002/ejhf.70026","DOIUrl":"https://doi.org/10.1002/ejhf.70026","url":null,"abstract":"AIMSThe PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC). We describe the baseline characteristics of participants in PARACHUTE-HF compared with prior HFrEF trials.METHODS AND RESULTSPARACHUTE-HF, a multicentre, active-controlled, open-label trial, enrolled 922 participants with confirmed CCC, New York Heart Association (NYHA) functional class II-IV, and left ventricular ejection fraction (LVEF) ≤40%. Participants were randomized 1:1 to sacubitril/valsartan (97/103 mg bid) or enalapril (10 mg bid). Enrolled participants (mean age: 64.2 years, 42.0% women) had a baseline LVEF of 29.8% (NYHA class II: 61.7%; NHYA class III/IV: 38.2%). History included hypertension (40.5%), atrial fibrillation/flutter (32.5%), ventricular arrhythmia (24.7%) and stroke (12.5%). The majority of patients had cardiac conduction abnormalities and 46.0% had conventional pacemaker, cardiac resynchronization therapy or implantable cardioverter-defibrillator. Mean systolic blood pressure was 118 mmHg, and median NT-proBNP level was 1730 pg/ml.CONCLUSIONSBaseline characteristics of this study highlight the unique clinical profile of patients with CCC-related HFrEF, including the high proportion of women affected, lower rates of comorbidities (hypertension/diabetes) and higher prevalence of stroke and pacemaker implantation when compared with other non-CCC-related HFrEF studies. These findings reinforce the need for dedicated heart failure treatments in this neglected subpopulation, particularly in Latin America where Chagas disease remains a significant public health issue.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"30 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter regarding the article 'Oral ferric maltol improves iron deficiency anaemia in patients with chronic heart failure'. 关于“口服麦芽糖醇铁改善慢性心力衰竭患者缺铁性贫血”一文的信函。
IF 18.2 1区 医学
European Journal of Heart Failure Pub Date : 2025-09-08 DOI: 10.1002/ejhf.70024
Peng Sun
{"title":"Letter regarding the article 'Oral ferric maltol improves iron deficiency anaemia in patients with chronic heart failure'.","authors":"Peng Sun","doi":"10.1002/ejhf.70024","DOIUrl":"https://doi.org/10.1002/ejhf.70024","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"24 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter regarding the article 'Effects of geranylgeranylacetone on diastolic and microvascular function in patients with heart failure with a preserved ejection fraction: A phase 2, randomized, placebo-controlled, crossover trial'. 关于文章“香叶酮对保留射血分数的心力衰竭患者舒张和微血管功能的影响:一项随机、安慰剂对照、交叉试验”的信。
IF 18.2 1区 医学
European Journal of Heart Failure Pub Date : 2025-09-08 DOI: 10.1002/ejhf.70039
Zongyu Yang,Liqiu Kou,Songjie Liao
{"title":"Letter regarding the article 'Effects of geranylgeranylacetone on diastolic and microvascular function in patients with heart failure with a preserved ejection fraction: A phase 2, randomized, placebo-controlled, crossover trial'.","authors":"Zongyu Yang,Liqiu Kou,Songjie Liao","doi":"10.1002/ejhf.70039","DOIUrl":"https://doi.org/10.1002/ejhf.70039","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"28 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrated trajectories of systolic and diastolic function differentially associate with risk for heart failure with preserved and reduced ejection fraction and proteomic profiles 收缩期和舒张期功能的综合轨迹与心力衰竭风险的差异与射血分数和蛋白质组学特征的保留和降低有关
IF 18.2 1区 医学
European Journal of Heart Failure Pub Date : 2025-09-02 DOI: 10.1002/ejhf.70015
Anne Marie Reimer Jensen, James C. Ross, Victoria Arthur, Michael E. Hall, Kunihiro Matsushita, Brandon Lennep, Pamela L. Lutsey, Tor Biering‐Sørensen, Amil M. Shah
{"title":"Integrated trajectories of systolic and diastolic function differentially associate with risk for heart failure with preserved and reduced ejection fraction and proteomic profiles","authors":"Anne Marie Reimer Jensen, James C. Ross, Victoria Arthur, Michael E. Hall, Kunihiro Matsushita, Brandon Lennep, Pamela L. Lutsey, Tor Biering‐Sørensen, Amil M. Shah","doi":"10.1002/ejhf.70015","DOIUrl":"https://doi.org/10.1002/ejhf.70015","url":null,"abstract":"AimsTo jointly model longitudinal measures of left ventricular ejection fraction (LVEF) and E/A ratio in late‐life, and to assess whether predicted trajectory membership is associated with heart failure risk.Methods and resultsUsing a Bayesian non‐parametric trajectory approach, trajectories were modelled among 747 Jackson Heart Study participants who underwent ≥2 echocardiograms in 2000–2004 (age 65 ± 5 years), 2011–2013 (75 ± 5), and 2018–2019 (81 ± 5). Using the resulting model, we predicted trajectory membership for 4419 distinct Atherosclerosis Risk in Communities (ARIC) study participants based on single time‐point measures of LVEF and E/A ratio (age 75 ± 5 years; ‘testing cohort’). Multivariable Cox models assessed the relationship between predicted trajectory and incident heart failure with preserved (HFpEF) and reduced ejection fraction (HFrEF). We evaluated associations of 4877 plasma proteins (SOMAscan) with predicted trajectory and performed Mendelian randomization to assess causal effects on LVEF and volume. Six trajectories were identified: pink (prevalence 50%) and light green (17%) – increasing LVEF, decreasing E/A ratio with age; red (22%) – no increase in LVEF; dark green (4%) – declining LVEF; orange (2%) – steeply declining LVEF, rising E/A ratio; and blue (4%) – rising E/A ratio despite increasing LVEF. In the testing cohort, red and dark green associated with HFrEF alone, blue with HFpEF alone, and orange with both compared to pink. Trajectory membership provided incremental value in predicting heart failure and HFpEF. Mendelian randomization identified potential causal effects of 13 trajectory‐associated proteins on LVEF and volume.ConclusionsBayesian non‐parametric modelling identifies cardiac function trajectories differentially associated with HFpEF and HFrEF and holds promise to improve risk prediction and enable therapeutic target discovery.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"66 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144930635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High prevalence of wild‐type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study 在患有腕管综合征、心力衰竭或左心室体积增大的老年人中,野生型转甲状腺素型心脏淀粉样变的患病率很高:CAPTURE研究
IF 18.2 1区 医学
European Journal of Heart Failure Pub Date : 2025-09-02 DOI: 10.1002/ejhf.70030
Alberto Aimo, Giuseppe Vergaro, Maria Concetta Pastore, Daniela Tomasoni, Vincenzo Castiglione, Riccardo Saro, Elisa Zaro, Antonio Maria Sammartino, Elisa Giacomin, Matteo Serenelli, Alberto Cipriani, Aldostefano Porcari, Andrea Di Lenarda, Marco Metra, Gianfranco Sinagra, Matteo Cameli, Marco Merlo, Michele Emdin
{"title":"High prevalence of wild‐type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study","authors":"Alberto Aimo, Giuseppe Vergaro, Maria Concetta Pastore, Daniela Tomasoni, Vincenzo Castiglione, Riccardo Saro, Elisa Zaro, Antonio Maria Sammartino, Elisa Giacomin, Matteo Serenelli, Alberto Cipriani, Aldostefano Porcari, Andrea Di Lenarda, Marco Metra, Gianfranco Sinagra, Matteo Cameli, Marco Merlo, Michele Emdin","doi":"10.1002/ejhf.70030","DOIUrl":"https://doi.org/10.1002/ejhf.70030","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"38 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144928251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low-dose digoxin improves cardiac function in patients with heart failure, preserved ejection fraction and atrial fibrillation - the RATE-AF randomized trial. 低剂量地高辛改善心力衰竭、保留射血分数和房颤患者的心功能——RATE-AF随机试验。
IF 10.8 1区 医学
European Journal of Heart Failure Pub Date : 2025-09-02 DOI: 10.1002/ejhf.70022
Karina V Bunting, Asgher Champsi, Simrat K Gill, Khalil Saadeh, A John Camm, Mary Stanbury, Sandra Haynes, Jonathon N Townend, Richard P Steeds, Dipak Kotecha
{"title":"Low-dose digoxin improves cardiac function in patients with heart failure, preserved ejection fraction and atrial fibrillation - the RATE-AF randomized trial.","authors":"Karina V Bunting, Asgher Champsi, Simrat K Gill, Khalil Saadeh, A John Camm, Mary Stanbury, Sandra Haynes, Jonathon N Townend, Richard P Steeds, Dipak Kotecha","doi":"10.1002/ejhf.70022","DOIUrl":"https://doi.org/10.1002/ejhf.70022","url":null,"abstract":"<p><strong>Aims: </strong>To compare the effect of digoxin versus beta-blockers on left ventricular function, in patients with permanent atrial fibrillation (AF) and symptoms of heart failure within the RATE-AF randomized trial.</p><p><strong>Methods and results: </strong>Blinded echocardiograms were performed at baseline and 12-month follow-up using a pre-defined imaging protocol and the index-beat approach. The change in systolic and diastolic function was assessed, stratified by left ventricular ejection fraction (LVEF). Overall, 145 patients completed follow-up, with median age 75 years (interquartile range 69-82) and 44% women. In 119 patients with baseline LVEF ≥50%, a significantly greater improvement in systolic function was noted in patients randomized to low-dose digoxin versus beta-blockers: adjusted mean difference for LVEF 2.3% (95% confidence interval [CI] 0.3-4.2; p = 0.021), s' 1.1 cm/s (95% CI 1.0-1.2; p = 0.001) and stroke volume 6.5 ml (95% CI 0.4-12.6; p = 0.037), with no difference in global longitudinal strain (p = 0.11) or any diastolic parameters. There were no significant differences between groups for patients with LVEF 40-49% and <40%. Digoxin reduced N-terminal pro-B-type natriuretic peptide compared to beta-blockers (geometric mean difference 0.77; 95% CI 0.64-0.92; p = 0.004), improved New York Heart Association functional class (odds ratio [OR] 11.3, 95% CI 4.3-29.8; p < 0.001) and modified European Heart Rhythm Association arrhythmia symptom class (OR 4.91, 95% CI 2.36-10.23; p < 0.001), with substantially less adverse events (incident rate ratio 0.21, 95% CI 0.13-0.31; p < 0.001). There were no interactions between treatment effects and baseline LVEF for these outcomes (interaction p = 0.62, 0.49, 0.07 and 0.13, respectively).</p><p><strong>Conclusions: </strong>Low-dose digoxin in patients with symptoms of heart failure, preserved LVEF and permanent AF leads to a significantly greater improvement in systolic function compared to treatment with beta-blockers.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.8,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Higher hospital volume is associated with lower mortality for patients with cardiogenic shock and mechanical circulatory support 较高的医院容量与心源性休克和机械循环支持患者的较低死亡率相关
IF 18.2 1区 医学
European Journal of Heart Failure Pub Date : 2025-08-31 DOI: 10.1002/ejhf.70025
Angela Dettling, Caroline Kellner, Jonas Sundermeyer, Benedikt N. Beer, Lisa Besch, Marvin Kriz, Stefan Kluge, Paulus Kirchhof, Stefan Blankenberg, Benedikt Schrage
{"title":"Higher hospital volume is associated with lower mortality for patients with cardiogenic shock and mechanical circulatory support","authors":"Angela Dettling, Caroline Kellner, Jonas Sundermeyer, Benedikt N. Beer, Lisa Besch, Marvin Kriz, Stefan Kluge, Paulus Kirchhof, Stefan Blankenberg, Benedikt Schrage","doi":"10.1002/ejhf.70025","DOIUrl":"https://doi.org/10.1002/ejhf.70025","url":null,"abstract":"AimsMortality for cardiogenic shock (CS) remains high. To improve outcomes, centralization of treatment in specialized centres, especially those with expertise in mechanical circulatory support (MCS), has been recommended. High‐volume centres may be able to provide standardized, better care. We analysed associations between centre volume and outcomes in Germany, a large country with multiple types of CS centres.Methods and resultsBased on data from all CS patients treated in Germany from 2017–2021, the association between annual CS/MCS hospital volume and in‐hospital mortality was assessed using adjusted Cox‐regression, and spline plots were used to assess case thresholds. Overall, 220 223 CS patients underwent treatment at 1232 hospitals; 435/1232 (35%) of these performed MCS therapy, although only few hospitals (60/435, 14%) performed &gt;25 MCS cases per year on average. Treatment at hospitals with a higher annual volume of CS and MCS cases was associated with a significantly lower mortality risk as compared to hospitals with a lower volume (upper third vs. lower two‐thirds; CS: hazard ratio [HR] 0.92, 95% confidence interval [CI] 0.91–0.94; <jats:italic>p</jats:italic> &lt; 0.001; MCS: HR 0.80, 95% CI 0.76–0.84; <jats:italic>p</jats:italic> &lt; 0.001). These associations were continuous without a detectable ceiling effect, with spline plots suggesting case thresholds of at least 90 CS cases/25 MCS cases per year.ConclusionsCare for patients with CS treated with and without MCS is associated with lower in‐hospital mortality in hospitals that manage high volumes of CS and MCS. This analysis indicates that centralization of CS care in specialized centres treating high volumes of patients with CS and MCS might improve outcomes.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"9 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2025-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144920672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Left ventricular ejection fraction and benefit of tricuspid valve interventions - insights from the international TRIGISTRY. 左心室射血分数和三尖瓣干预的益处-来自国际TRIGISTRY的见解。
IF 10.8 1区 医学
European Journal of Heart Failure Pub Date : 2025-08-30 DOI: 10.1002/ejhf.3797
Gregor Heitzinger, Julien Dreyfus, Varius Dannenberg, Yan Topilsky, Giovanni Benfari, Nina Ajmone Marsan, Maurizio Taramasso, Giulio Russo, Yohann Bohbot, Christos Iliadis, Marcel Weber, Luis Nombela-Franco, Andrea Eixerés-Esteve, Baptiste Bazire, Bernard Iung, Jean-François Obadia, Rodrigo Estevez Loureiro, Elisabeth Riant, Erwan Donal, Gilbert Habib, Yoan Lavie-Badie, Jörg Hausleiter, Lucas Stolz, Luigi Badano, Thierry Le Tourneau, Augustin Coisne, Thomas Modine, Fabien Praz, Jose Luis Zamorano, Ralph Stephan von Bardeleben, Rebecca T Hahn, Neil Fam, Horst Sievert, Denisa Muraru, Mariana Adamo, Samuel Heuts, Mohammed Nejjari, Vincent Chan, Michele De Bonis, Manuel Carnero-Alcazar, Volker Rudolph, Juan Crestanello, Philipp Lurz, Jeroen Bax, Roja Gauda, Jordan Bernick, George A Wells, Francesco Maisano, Maurice Enriquez-Sarano, Philipp Bartko, David Messika-Zeitoun
{"title":"Left ventricular ejection fraction and benefit of tricuspid valve interventions - insights from the international TRIGISTRY.","authors":"Gregor Heitzinger, Julien Dreyfus, Varius Dannenberg, Yan Topilsky, Giovanni Benfari, Nina Ajmone Marsan, Maurizio Taramasso, Giulio Russo, Yohann Bohbot, Christos Iliadis, Marcel Weber, Luis Nombela-Franco, Andrea Eixerés-Esteve, Baptiste Bazire, Bernard Iung, Jean-François Obadia, Rodrigo Estevez Loureiro, Elisabeth Riant, Erwan Donal, Gilbert Habib, Yoan Lavie-Badie, Jörg Hausleiter, Lucas Stolz, Luigi Badano, Thierry Le Tourneau, Augustin Coisne, Thomas Modine, Fabien Praz, Jose Luis Zamorano, Ralph Stephan von Bardeleben, Rebecca T Hahn, Neil Fam, Horst Sievert, Denisa Muraru, Mariana Adamo, Samuel Heuts, Mohammed Nejjari, Vincent Chan, Michele De Bonis, Manuel Carnero-Alcazar, Volker Rudolph, Juan Crestanello, Philipp Lurz, Jeroen Bax, Roja Gauda, Jordan Bernick, George A Wells, Francesco Maisano, Maurice Enriquez-Sarano, Philipp Bartko, David Messika-Zeitoun","doi":"10.1002/ejhf.3797","DOIUrl":"https://doi.org/10.1002/ejhf.3797","url":null,"abstract":"<p><strong>Aims: </strong>The impact of treatment for tricuspid regurgitation (TR) across different levels of left ventricular ejection fraction (LVEF) remains uncertain. This study aimed to compare the outcomes of surgical and transcatheter tricuspid valve interventions (TTVI) to conservative (medical) management across LVEF categories.</p><p><strong>Methods and results: </strong>Patients with severe isolated TR from the TRIGISTRY, a multicentre international registry, were categorized based on LVEF (preserved ejection fraction [pEF]: ≥50%, mildly reduced ejection fraction [mrEF]: 41-49%, and reduced ejection fraction [rEF]: ≤40%). We assessed the impact of treatment modality and procedural success (mild-to-moderate or lower residual TR) on 2-year survival within each LVEF category. Among 2384 patients, 1383 had pEF, 400 had mrEF, and 601 had rEF. Compared to conservative management, surgery (p < 0.0005) and TTVI (p < 0.0001) were associated with a survival benefit in patients with pEF. No significant survival advantage was observed in patients with mrEF (p = 0.28 for both), nor in those with rEF (p = 0.76 and p = 0.22, respectively). Similar results were obtained when surgical and transcatheter interventions were grouped (p < 0.0001, p = 0.17 and p = 0.29 in patients with pEF, mrEF and rEF, respectively). Patients with residual TR after TTVI exhibited a trend toward worse survival compared to those managed conservatively across all LVEF categories (p = 0.47, p = 0.33 and p = 0.008 in pEF, mrEF and rEF, respectively).</p><p><strong>Conclusions: </strong>Transcatheter tricuspid valve intervention, whether surgical or transcatheter-based, was associated with improved survival in patients with pEF but not in those with mrEF or rEF. Residual TR remained a significant prognostic factor across the entire LVEF spectrum. These findings highlight the need for careful patient selection when considering TTVI in individuals with rEF.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.8,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144937291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信